Literature DB >> 24488088

High-dose intravenous immunoglobulin exerts neuroprotective effect in the rat model of neonatal asphyxia.

Bo Chen1, Jeong Seon Yoon2, Bingren Hu1, Milan Basta3.   

Abstract

BACKGROUND: Neonatal asphyxia is one of the leading causes of death in newborn and permanent neurological disabilities in surviving children. The underlying hypoxic-ischemic (HI) injury triggers an inflammatory response leading to neuronal damage. Here, we tested the hypothesis that high-dose intravenous immunoglobulin (IVIG) could exert immunomodulatory effect in rat pups subjected to HI injury.
METHODS: HI injury was induced in 7-d-old pups by ligating the common carotid artery followed by exposure to 8% oxygen for 2 h. Brain infarction was evaluated by imaging stained coronal brain sections. Neurological deficits were assessed in weeks 1 through 4 after HI. Western blotting and immunohistochemistry were used to assess complement fragment deposition in the brain tissue.
RESULTS: Treatment with IVIG at 2 g/kg significantly and in a dose-responsive manner reduced brain infarction size as well as mortality and neurological deficits caused by HI. Anatomical and functional improvements in IVIG-treated pups correlated with decreased deposition of C3b complement fragments in the injured brain hemisphere.
CONCLUSION: IVIG significantly improved the outcome of HI injury in rat pups and could potentially be used for the treatment of human neonatal asphyxia to target proinflammatory complement fragments.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24488088     DOI: 10.1038/pr.2014.12

Source DB:  PubMed          Journal:  Pediatr Res        ISSN: 0031-3998            Impact factor:   3.756


  1 in total

1.  IVIg attenuates complement and improves spinal cord injury outcomes in mice.

Authors:  Faith H Brennan; Nyoman D Kurniawan; Jana Vukovic; Perry F Bartlett; Fabian Käsermann; Thiruma V Arumugam; Milan Basta; Marc J Ruitenberg
Journal:  Ann Clin Transl Neurol       Date:  2016-05-25       Impact factor: 4.511

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.